Mark H. Libenson, M.D.,C.M.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 8 | 2024 | 298 | 1.400 |
Why?
|
| Epilepsy | 14 | 2023 | 3290 | 0.800 |
Why?
|
| Seizures | 12 | 2024 | 2956 | 0.460 |
Why?
|
| Anticonvulsants | 9 | 2022 | 1906 | 0.450 |
Why?
|
| Electroencephalography | 16 | 2024 | 6224 | 0.420 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2009 | 177 | 0.320 |
Why?
|
| Dexmedetomidine | 1 | 2009 | 319 | 0.250 |
Why?
|
| Conscious Sedation | 1 | 2009 | 532 | 0.250 |
Why?
|
| Triazoles | 3 | 2014 | 903 | 0.200 |
Why?
|
| Hemispherectomy | 1 | 2022 | 41 | 0.200 |
Why?
|
| Monitoring, Physiologic | 3 | 2021 | 1780 | 0.200 |
Why?
|
| Vigabatrin | 1 | 2021 | 88 | 0.180 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2003 | 352 | 0.170 |
Why?
|
| Infant | 15 | 2024 | 36202 | 0.160 |
Why?
|
| Child, Preschool | 15 | 2020 | 42251 | 0.160 |
Why?
|
| Acetazolamide | 1 | 1999 | 96 | 0.160 |
Why?
|
| Neonatal Screening | 1 | 2003 | 597 | 0.160 |
Why?
|
| Epilepsies, Partial | 1 | 2022 | 431 | 0.160 |
Why?
|
| Spasm | 3 | 2024 | 130 | 0.160 |
Why?
|
| Furosemide | 1 | 1999 | 170 | 0.150 |
Why?
|
| Occipital Lobe | 1 | 1999 | 374 | 0.150 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2017 | 19 | 0.140 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2017 | 88 | 0.130 |
Why?
|
| Diuretics | 1 | 1999 | 610 | 0.130 |
Why?
|
| Status Epilepticus | 2 | 2018 | 460 | 0.120 |
Why?
|
| Child | 17 | 2023 | 80156 | 0.120 |
Why?
|
| Brain | 4 | 2019 | 27103 | 0.120 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2016 | 617 | 0.120 |
Why?
|
| Retrospective Studies | 15 | 2024 | 80575 | 0.110 |
Why?
|
| Infant, Premature, Diseases | 1 | 1999 | 710 | 0.110 |
Why?
|
| Consciousness Disorders | 1 | 2017 | 441 | 0.100 |
Why?
|
| Hydrocephalus | 1 | 1999 | 764 | 0.100 |
Why?
|
| Epilepsy, Generalized | 1 | 1994 | 178 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 1994 | 351 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2019 | 900 | 0.090 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2017 | 1017 | 0.090 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2013 | 227 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2014 | 785 | 0.080 |
Why?
|
| Brain Stem | 1 | 1994 | 858 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1461 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2023 | 3267 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2020 | 2053 | 0.080 |
Why?
|
| Critical Illness | 1 | 2021 | 2722 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 36430 | 0.080 |
Why?
|
| Hippocampus | 1 | 2021 | 3763 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2014 | 1132 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 2656 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2071 | 0.070 |
Why?
|
| Syndrome | 2 | 2024 | 3268 | 0.070 |
Why?
|
| Treatment Outcome | 11 | 2023 | 64645 | 0.070 |
Why?
|
| Adolescent | 11 | 2018 | 88305 | 0.070 |
Why?
|
| Spinal Cord | 1 | 1994 | 1817 | 0.070 |
Why?
|
| Sleep Stages | 1 | 2009 | 693 | 0.060 |
Why?
|
| Humans | 29 | 2024 | 761326 | 0.060 |
Why?
|
| Male | 20 | 2023 | 360621 | 0.060 |
Why?
|
| Female | 19 | 2023 | 392485 | 0.060 |
Why?
|
| Critical Care | 1 | 2017 | 2697 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2014 | 2690 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2853 | 0.060 |
Why?
|
| Apgar Score | 1 | 2003 | 126 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 1496 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 5776 | 0.050 |
Why?
|
| Infant, Newborn | 5 | 2020 | 26211 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2014 | 3905 | 0.050 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 39108 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2003 | 916 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2022 | 555 | 0.040 |
Why?
|
| Young Adult | 6 | 2017 | 59196 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2023 | 751 | 0.040 |
Why?
|
| Sleep | 1 | 2014 | 4765 | 0.040 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1999 | 195 | 0.040 |
Why?
|
| Spinal Puncture | 1 | 1999 | 282 | 0.040 |
Why?
|
| Hospital Units | 1 | 2018 | 142 | 0.030 |
Why?
|
| Age of Onset | 1 | 2024 | 3303 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 6309 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2022 | 3538 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2018 | 551 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2003 | 6231 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2018 | 354 | 0.030 |
Why?
|
| Kidney Calculi | 1 | 1999 | 463 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2003 | 1508 | 0.030 |
Why?
|
| Hemiplegia | 1 | 1994 | 136 | 0.030 |
Why?
|
| Drainage | 1 | 1999 | 1156 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 1994 | 623 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 74152 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1999 | 2256 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2023 | 41440 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1994 | 542 | 0.020 |
Why?
|
| Vomiting | 1 | 2014 | 652 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 12059 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2018 | 2242 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15262 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9333 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1999 | 5970 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2014 | 54405 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 6422 | 0.010 |
Why?
|
| Adult | 5 | 2017 | 221122 | 0.010 |
Why?
|
| Genotype | 1 | 2017 | 12982 | 0.010 |
Why?
|
| Time Factors | 2 | 2014 | 39974 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 10764 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16603 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1994 | 14597 | 0.010 |
Why?
|
| Hospitalization | 1 | 2018 | 10715 | 0.010 |
Why?
|
| Pediatrics | 1 | 2010 | 3594 | 0.010 |
Why?
|